What it will take to meet CEPI’s 100-day vaccine goal for the next pandemic
A vaccine library, Coca-Cola machine-type manufacturing options, and some immunology lessons from the cancer field
A vaccine library, Coca-Cola machine-type manufacturing options, and some immunology lessons from the cancer field.
As CEPI looks to prepare for the next pandemic, it has set a lofty goal to reduce to 100 days the time from sequencing the pathogen to a regulatory submission of a vaccine. But meeting that mark will require invention of technologies that don’t yet exist, layered on top of step changes in almost all stages of the process from day one to 100.
It may also require a scientific shift in vaccinology away from the focus on neutralizing antibodies, towards a broader recruitment of the immune system, catching up with advances made in immunology that other fields, notably cancer, have already embraced.
The Coalition for Epidemic Preparedness Innovations is not waiting for this pandemic to be over before preparing for the next one. It launched a plan on March 10 to raise $3.5 billion for its five-year plan for the 100-day goal, but wants $1 billion of the sum now to expedite COVID-19 vaccine R&D for a second wave of products, in particular to battle the rise of variants of SARS-CoV-2.
CEPI will issue a request for proposals before the end of March that will focus on